Results 111 to 120 of about 353,326 (255)

A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]

, 2007
We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross, Pavlakis, Nick, Stordal, Britta   +2 more
core   +1 more source

MTMR6 downregulation contributes to cisplatin resistance in oral squamous cell carcinoma

Cancer Cell International
Background The therapeutic effectiveness of cisplatin, a widely used chemotherapy drug for oral squamous cell carcinoma (OSCC), is often compromised by resistance, making it difficult to predict treatment outcomes.
Kah Young Lee, Su Young Oh, Heon-Jin Lee, Tae-Geon Kwon, Jin-Wook Kim, Chang-Geol Shin, Su-Hyung Hong, So-Young Choi   +7 more
doaj   +1 more source

Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design [PDF]

, 2009
The main task of the medicinal chemist is to design molecules that interact specifically with derailed or degenerating processes in a diseased organism, translating the available knowledge of pathobiochemical and physiological data into chemically ...
Bruijnincx, Pieter C. A., Sadler, P. J.
core   +1 more source

Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin

Biomedical & Pharmacology Journal, 2019
Cisplatin is a chemotherapeutic drug that has been used in the treatment of various types of human cancers such as ovarian, lung, head and neck, testicular and bladder.
S. Aldossary
semanticscholar   +1 more source

Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway. [PDF]

, 2015
Tumor recurrence remains an obstacle after liver surgery, especially in living donor liver transplantation (LDLT) for patients with hepatocellular carcinoma (HCC).
Geng, Wei, Li, Chang-Xian, Ling, Chang-Chun, Liu, Xiao-Bing, Lo, Chung-Mau, Ma, Yuen-Yuen, Man, Kwan, Ng, Kevin TP, Qi, Xiang, Zhai, Yuan   +9 more
core   +1 more source

Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts [PDF]

, 2013
Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from problems of resistance and side-effects. Photoactivatable PtIV prodrugs offer the potential of targeted drug release and new mechanisms of action.
Bancroft, Brabec, Brabec, Brabec, Butler, Caradonna, Coluccia, Dhara, Eastman, Eastman, Farrell, Farrer, Farrer, Fichtinger-Schepman, Guddneppanavar, Hall, Hamers, Harper, Intini, Jamieson, Kasparkova, Kasparkova, Kauffman, Keck, Kelland, Lau, Lemaire, Mackay, Mackay, Mackay, Najajreh, Ohndorf, O’Dwyer, Pantoja, Phillips, Pracharova, Pregosin, Prokop, Reedijk, Ronconi, Salassa, Salassa, Salassa, Salassa, Siddik, Stehlíková, Still, Suchánková, Tai, Vinje, Vlček, Wang, Westendorf, Westendorf, Westendorf, Wong, Yao, Zenker   +57 more
core   +1 more source

Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma

Molecular & Cellular Oncology
Cisplatin is the commonly used chemotherapeutic drug in treatment of various cancers. However, development of resistance towards cisplatin results in tumor recurrence.
Ankit P. Jain, Vivek Ghose, Srijon Munshi, Firdous A. Bhat, Gourav Dey, Vishalakshi Nanjappa   +5 more
doaj   +1 more source

Cisplatin decreases HOXA13 and alphaVBeta3 integrin levels in the uterus

Taiwanese Journal of Obstetrics & Gynecology, 2021
Objective: To examine the effects of cisplatin on uterine histology and implantation molecules and the possible protective role of recombinant Klotho administration on uterine histology and uterine receptivity in mice exposed to cisplatin.
Mustafa Albayrak, Ismail Biyik, Fikriye Yasemin Ozatik, Orhan Ozatik, Neziha Senem Ari, Yasemin Teksen, Ozlem Erten   +6 more
doaj  

Cycloaurated GoId (III) complexes- Possible alternatives to cisplatin? [PDF]

, 2009
The serendipitous discovery of the anti-tumour activity of cisplatin [cis-PtCI₂(NH₃)₂] in 1969 has led to increased interest in the development of new metal-based anti-cancer drugs.
Henderson, William, Kilpin, Kelly Joan
core   +1 more source

Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]

, 2010
The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp, Harreus, Ulrich, Reiter, Maximilian, Schwenk-Zieger, Sabina   +3 more
core   +1 more source